东宝生物(300239) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥229,684,681.49, representing a 69.39% increase year-over-year[5] - Net profit attributable to shareholders was ¥29,809,651.68, a significant increase of 381.33% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥27,672,248.86, up 479.52% year-over-year[5] - The basic earnings per share for the period was ¥0.0502, reflecting a 321.85% increase compared to the same quarter last year[5] - The company's operating revenue for Q3 2022 reached ¥706,043,743.51, an increase of 71.26% compared to ¥412,267,239.59 in the same period last year[12] - Operating profit for the quarter was ¥107,490,911.86, compared to ¥17,011,668.55 in the previous year, reflecting a substantial growth[31] - The net profit for the third quarter of 2022 was ¥92,439,092.18, a significant increase from ¥13,670,658.88 in the same period last year, representing a growth of approximately 576%[32] - The net profit attributable to shareholders of the parent company was ¥87,784,562.99, compared to ¥13,744,660.50 in the previous year, indicating a year-over-year increase of about 537%[32] - The basic and diluted earnings per share for the third quarter were both ¥0.1479, up from ¥0.0248 in the prior year, reflecting an increase of approximately 497%[32] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥2,219,279,610.42, a 5.07% increase from the end of the previous year[5] - Total liabilities decreased to ¥486,400,284.44 from ¥508,580,671.06, showing improved financial stability[29] - The company's equity attributable to shareholders increased to ¥1,506,877,799.19 from ¥1,422,692,834.57, reflecting a growth of 5.9%[29] - Current assets totaled ¥971,578,588.47, an increase of 8.8% from ¥892,592,899.38[29] - Non-current assets rose to ¥1,247,701,021.95, compared to ¥1,219,647,603.86 at the start of the year[29] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥126,730,842.75, showing a 401.86% increase[5] - The net cash flow from operating activities increased significantly by 401.86% to ¥126,730,842.75, compared to ¥25,252,201.87 in the previous year[13] - Cash inflow from sales of goods and services was ¥496,962,022.72, compared to ¥249,580,843.04 in the previous year, indicating an increase of about 99.4%[34] - The net cash flow from financing activities was ¥127,868,845.94, down from ¥254,532,800.08 in the same period last year, reflecting a decrease of about 50%[36] - The company reported cash outflows from investing activities totaling ¥167,582,255.61, a decrease from ¥334,263,088.04 in the previous year, showing a reduction of approximately 50%[35] Research and Development - R&D expenses surged by 149.80% to ¥17,057,544.09, up from ¥6,828,546.10, driven by increased investment in research and the inclusion of Yiqing Bio in the consolidated financial statements[12] - Research and development expenses for the quarter were ¥17,057,544.09, significantly higher than ¥6,828,546.10 in the same period last year, indicating a focus on innovation[31] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,574, with no preferred shareholders[15] - The top shareholder, Qingdao Guoen Technology Co., Ltd., holds 21.18% of the shares, amounting to 125,711,022 shares[15] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 40.54% to ¥6,741,472.07, indicating higher prepayments from customers[10] - The income tax expense rose dramatically by 362.14% to ¥15,439,361.35, up from ¥3,340,873.70, due to increased profits[12] - The company experienced a significant increase in other income, which rose by 2376.26% to ¥642,902.56, compared to ¥25,962.63 in the previous year[12] - The company reported a net loss from investments of ¥718,952.78, an improvement of 57.09% from a loss of ¥1,675,448.37 in the prior period[12] Corporate Developments - The company completed the employee stock ownership plan, enhancing employee cohesion and corporate culture[21][22] - The company successfully increased capital for its subsidiary Yiqing Bio, completing the industrial and commercial change registration[23] - The company established two new subsidiaries to advance its multi-point terminal business strategy and launched new products including collagen peptide drinks and enzyme powders[25] - The company is actively developing e-commerce live streaming to promote star products and strengthen terminal operations[25] - The company optimized raw material procurement and production efficiency, contributing to improved operational performance[20] - The company merged with its subsidiary Yiqing Bio, resulting in increased sales revenue and profit[20] Audit and Reporting - The third quarter report was not audited, indicating that the figures presented are preliminary and subject to change[37]